Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
No additional AE; HCP calling to report an AE regarding the MMR II vaccine. HCP stated that a 24 year old male patient received his first dose of the VARIVAX vaccine 7 days ago. HCP reported that the same patient received his first dose of the MMR II vaccine today. HC; This spontaneous report was received from a pharmacist and refers to a(n) 24-year-old male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 10-Sep-2025, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date were not reported). On 17-Sep-2025, the was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date were not reported) (Inappropriate schedule of product administration). No additional adverse event reported (no adverse event).
sterile diluent